B1-Ala

General Information


DRACP ID  DRACP00517

Peptide Name   B1-Ala

Sequence  VKRFKKFFRKLKKAV

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Cathelicidin-BF15 C-terminal amidated derivative B1

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=8.9 µM MTT assay 48h 1
K562 Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia Leukemia IC50=8.6 µM MTT assay 48h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  GES-1: IC50=87.1 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00517

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C94H159N27O16

Absent amino acids  CDEGHIMNPQSTWY

Common amino acids  K

Mass  217335

Pl  12.58

Basic residues  8

Acidic residues  0

Hydrophobic residues  7

Net charge  8

Boman Index  -3939

Hydrophobicity  -66.67

Aliphatic Index  71.33

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25462264

Title  Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities

Doi 10.1016/j.ejmech.2014.10.072

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.